



COLORADO
 Department of Health Care
 Policy & Financing

Drug Utilization Review Board
MEETING AGENDA
 November 14, 2023
 Open Session 1:00 pm to 5:00 pm

Zoom Link will be posted prior to the meeting at
<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado’s Medicaid program

DUR Board Members	DUR Team
Liza Claus, PharmD (Chair) Brian Jackson, MD, MA (Vice Chair) Todd Brubaker, DO Shilpa Klocke, PharmD Patricia Lanus, BSPHarm, MHA Kenneth MacIntyre, DO Ingrid Pan, PharmD	Jeffrey Taylor, PharmD (HCPF) Veronia Garcia, PharmD (HCPF) Rachele Poissant, PharmD (HCPF) Julia Rawlings, PharmD (CO-DUR) Robert L Page II, PharmD, MSPH (CO-DUR) Gina Moore, PharmD, MBA (CO-DUR) Heather Anderson, PhD (CO-DUR) Garth Wright, MPH (CO-DUR) Nicholas Mendola, MPH (CO-DUR)

1. Call to Order
2. Roll Call and Introductions
3. Virtual Meeting Information and General Announcements
4. Colorado Department of Health Care Policy and Financing Updates
5. Final Approval of Minutes from the August 8, 2023 Meeting
6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

Presentations:

- Agenda items must be approved in advance, including requests to present information. Please contact DUR Pharmacist Jeffrey Taylor at jeffrey.taylor@state.co.us
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours prior to the start of the meeting

7. Clinical Updates and General Orders

- FDA New Product & Safety Updates
- Quarterly Module Summaries
- Retrospective DUR Reports
- Quarterly Drug Utilization Reports

8. New Business (open for public testimony and DUR Board review)

A. Proposed Coverage Criteria for Preferred Drug List (PDL) Drug Classes

(Current PDL available for reference at <https://hcpf.colorado.gov/pharmacy-resources#PDL>)

- Hepatitis C Virus Treatments
 - Direct Acting Antivirals
 - Ribavirin
- Human Immunodeficiency Virus (HIV) Treatments
- Targeted Immune Modulators
- Newer Hereditary Angioedema (HAE) Products

Mass review drug classes

- Antibiotics, Inhaled
- Antiherpetic Agents - Oral, Topical
- Fluoroquinolones, Oral
- Immune Globulins
- Antihistamines
 - Newer Generation
 - Antihistamine/Decongestant Combinations
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Methotrexate Products
- Epinephrine Products
- Respiratory Agents
 - Inhaled Anticholinergics & Combinations
 - Inhaled Beta2 Agonists (Short & Long-Acting)
 - Inhaled Corticosteroids & Combinations
 - Phosphodiesterase Inhibitors (PDEIs)

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review, based on board vote.*

B. Proposed Coverage Criteria for Non-PDL Products

(Current coverage criteria for non-PDL products can be referenced on Appendix P at <https://hcpf.colorado.gov/pharmacyresources#PDL> for the pharmacy benefit and on Appendix Y at <https://hcpf.colorado.gov/physician-administered-drugs> for the medical benefit. Products listed below that are undergoing initial review of newly proposed criteria will not be listed on the posted documents until such time that proposed criteria undergoes review and finalization)

- Filspari (sparsentan)
- Skyclarys (omaveloxolone)
- Elfabrio (pegunigalsidase alfa)
- Vyjuvek (beremagene geperpavec-svdt)
- Rystiggo (rozanolixizumab)
- Ycanth (cantharidin)
- Xdemvy (lotilaner)

9. Adjournment

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator or send an email to hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.